GSK Switzerland

GSK has been a fixture of the Swiss healthcare landscape since 2001, and the consolidation of its operations in Baar represents a mature, collaborative model of innovation. The site acts as a collaborative base for experts from the Swiss affiliate alongside colleagues dedicated to regional and global roles. While the hub leads critical R&D functions – including Medical Affairs, Regulatory Affairs, and Clinical Research – the Swiss organisation focuses on providing patients with access to innovative medicines and vaccines in respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

The company’s presence in Baar leverages the unique status of Zug as a premier “Pharma Canton”, offering unparalleled infrastructure and access to a highly skilled, international talent pool. As a key location within the Greater Zurich Area, the region is perfectly suited to GSK’s diverse workforce, which represents nearly 30 nationalities. Combined with the region’s exceptional quality of life, this location provides the ideal foundation for the team to thrive. Under the guiding principle “Ahead Together”, GSK continues to combine science and technology to prevent disease and improve patient outcomes both in Switzerland and across the globe.

Choosing Baar in the Greater Zurich Area for their Oncology Hub reflects GSK’s commitment to innovation and excellence in healthcare. Zug’s reputation as a 'Pharma Canton', known for its concentration of industry leaders, excellent connectivity, and substantial talent pool, makes it an ideal location for biotech and pharmaceutical companies looking to expand. Moreover, the region offers a high quality of life with beautiful landscapes, making it a great place to not only work but also live and thrive. From here, GSK continues to lead advancements in oncology, combining science, talent, and technology to transform the lives of patients worldwide.